Veregen

Veregen is a botanical drug product used for the topical treatment of external genital and perianal warts caused by the Human Papillomavirus (HPV). It is derived from green tea leaves and is manufactured by the German pharmaceutical company Medigene.

History[edit | edit source]

Veregen was first approved by the U.S. Food and Drug Administration (FDA) in 2006. It was the first botanical drug approved by the FDA for the treatment of warts caused by HPV.

Composition[edit | edit source]

The active ingredient in Veregen is a partially purified fraction of the water extract of green tea leaves from Camellia sinensis, and it contains a defined mixture of catechins. The most abundant catechin in Veregen is Epigallocatechin gallate (EGCG).

Mechanism of Action[edit | edit source]

Veregen's mechanism of action is not completely understood. However, it is believed to work by inhibiting the growth and spread of HPV, thereby reducing the size and number of warts.

Usage[edit | edit source]

Veregen is applied topically three times daily until complete clearance of all warts, but no longer than 16 weeks. It is not recommended for use in children under 18 years of age.

Side Effects[edit | edit source]

Common side effects of Veregen include local skin and application site reactions including redness, itching, burning, pain, sores, swelling, hardening, and rash.